RxDoctor Payments Data

Paul Potach, DPM

Podiatrist · Wheeling, ILNPI 1073627410

Payments from drug & device makers

What this record shows

This record is dominated by other: $40,764 of the $45,035 with a category attached, or 90.5%. Convatec Inc. accounts for 90.5% of it on its own, with 11 other manufacturers making up the rest. 2025 is the largest year on record at $41,659, more than ten times the $56 reported in 2019. Among podiatrist clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$45,035in general payments, 2019–2025

Across 124 payments — averaging $363.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Convatec Inc.$41K
  • Organogenesis Inc.$3K
  • Amgen$485
  • Cardiovascular Systems Inc.$166
  • Nevro Corp.$146
  • Next Science LLC$59
  • plus $72 from 6 others

What the payments were for

  • Consulting fees$130%
  • Food & beverage$4,2589%
  • Other$40,76491%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$45,035 in reported general payments places this provider in the 95th percentile of 409 podiatrist providers in Illinois.

See all podiatrist providers in Illinois

Medicare billing

Part B allowed, 2024
$4,517,243
Medicare patients
258
Services billed
2,731

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ketoconazole29$559
Terbinafine Hcl17$114

Paid to pharmacies, not to this prescriber.

Other podiatrist in Wheeling

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →